TABLE 4.
Pharmacological parameters of the results shown in Fig. 4, A–C
Top and bottom are expressed as fold of basal, and log EC50 is expressed as logged EC50 (M).
| ZnCl2 |
||||||
|---|---|---|---|---|---|---|
| 316 μM (N = 3) | 100 μM (N = 13) | 31.6 μM (N = 3) | 10 μM (N = 3) | 3.16 μM (N = 3) | 0 μM (N = 13) | |
| GPR39-C3 | ||||||
| Top | 22.76 ± 0.89 | 7.68 ± 0.15 | 3.18 ± 0.13 | N.D. | N.D. | N.D. |
| Bottom | 2.33 ± 0.24 | 1.38 ± 0.05 | 1.29 ± 0.04 | N.D. | N.D. | N.D. |
| Log EC50 | −7.05 ± 0.07 | −6.72 ± 0.04 | −6.17 ± 0.08 | N.D. | N.D. | N.D. |
| Hill slope | 0.87 ± 0.10 | 1.01 ± 0.08 | 1.70 ± 0.45 | N.D. | N.D. | N.D. |
| LY2784544 | ||||||
| Top | 18.86 ± 0.38 | 7.24 ± 0.19 | 1.96 ± 0.07 | N.D. | N.D. | N.D. |
| Bottom | 2.04 ± 0.21 | 1.20 ± 0.10 | 1.12 ± 0.03 | N.D. | N.D. | N.D. |
| Log EC50 | −7.75 ± 0.05 | −7.37 ± 0.08 | −6.47 ± 0.08 | N.D. | N.D. | N.D. |
| Hill slope | 1.14 ± 0.12 | 1.13 ± 0.37 | 3.31 ± 3.73 | N.D. | N.D. | N.D. |
| GSK2636771 | ||||||
| Top | 16.41 ± 0.51 | 4.80 ± 0.12 | N.D. | N.D. | N.D. | N.D. |
| Bottom | 1.93 ± 0.18 | 1.10 ± 0.05 | N.D. | N.D. | N.D. | N.D. |
| Log EC50 | −7.12 ± 0.06 | −7.09 ± 0.05 | N.D. | N.D. | N.D. | N.D. |
| Hill slope | 1.10 ± 0.14 | 1.29 ± 0.17 | N.D. | N.D. | N.D. | N.D. |
N.D., could not determine.